Cue Biopharma reports Q4 EPS (13c), consensus (14c)

Reports Q4 revenue $1.58M, consensus $1.7M. “During 2024 and Q1 2025, we made significant progress shaping the company for success,” said Daniel Passeri, chief executive officer of Cue Biopharma (CUE). “We believe that the ongoing advancement of our prioritized autoimmune programs and the implementation of a highly focused strategic business model, support our ability to exploit the potentially disruptive opportunity of our Immuno-STAT platform, specifically CUE-401.”